TY - JOUR
T1 - Monitoring Neurodegeneration in Glaucoma
T2 - Therapeutic Implications
AU - Ban, Norimitsu
AU - Siegfried, Carla J.
AU - Apte, Rajendra S.
N1 - Funding Information:
Washington University in St. Louis School of Medicine has filed intellectual property based on these findings with R.S.A. as inventor. This work was supported by National Institutes of Health (NIH) grants R01 EY019287 (R.S.A), R01 EY021515 (C.J.S.), and P30EY02687 (Vision Core Grant); the Starr Foundation; the Kuzma Family, Research to Prevent Blindness (RPB) Physician Scientist Award (R.S.A.), the RPB Nelson trust Award (R.S.A.), and an unrestricted grant from RPB to the Department of Ophthalmology, Washington University in St. Louis School of Medicine. We thank Tae Jun Lee (Washington University in St. Louis) for graphic support.
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2018/1
Y1 - 2018/1
N2 - Glaucoma is one of the leading causes of blindness globally, and is characterized by loss of retinal ganglion cells (RGCs). Because vision loss in glaucoma is not reversible, therapeutic interventions early in disease are highly desirable. However, owing to the current limitations in evaluating glaucomatous neurodegeneration, it is challenging to monitor the disease severity and progression objectively, and to design rational therapeutic strategies accordingly. Therefore, there is a clear need to identify quantifiable molecular biomarkers of glaucomatous neurodegeneration. As such, in our opinion, molecular biomarker(s) that specifically reflect stress or death of RGCs, and which correlate with disease severity, progression, and response to therapy, are highly desirable.
AB - Glaucoma is one of the leading causes of blindness globally, and is characterized by loss of retinal ganglion cells (RGCs). Because vision loss in glaucoma is not reversible, therapeutic interventions early in disease are highly desirable. However, owing to the current limitations in evaluating glaucomatous neurodegeneration, it is challenging to monitor the disease severity and progression objectively, and to design rational therapeutic strategies accordingly. Therefore, there is a clear need to identify quantifiable molecular biomarkers of glaucomatous neurodegeneration. As such, in our opinion, molecular biomarker(s) that specifically reflect stress or death of RGCs, and which correlate with disease severity, progression, and response to therapy, are highly desirable.
KW - aqueous humor
KW - biomarker
KW - glaucoma
KW - growth differentiation factor 15 (GDF15)
KW - neurodegeneration
KW - retinal ganglion cell
UR - http://www.scopus.com/inward/record.url?scp=85038963018&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2017.11.004
DO - 10.1016/j.molmed.2017.11.004
M3 - Review article
C2 - 29233479
AN - SCOPUS:85038963018
SN - 1471-4914
VL - 24
SP - 7
EP - 17
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 1
ER -